{'fraction_non_alphanumeric': 0.020606060606060607, 'fraction_numerical': 0.0048484848484848485, 'mean_word_length': 5.3538461538461535, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise.

In the twenty years since George Glenner identified the amyloid beta-protein (Abeta), advances in understanding the biochemical pathology, genetics and cell biology of Alzheimer's disease have led to a detailed molecular hypothesis for the genesis of AD and brought us into human trials of anti-amyloid agents. The ability to study Abeta dynamically in cultured cells and in vivo derives from the recognition in 1992 that Abeta is a normal product of cellular metabolism throughout life and circulates as a soluble peptide in biological fluids. Here, I review the background underlying this discovery and then discuss its implications for research on Alzheimer's disease, particularly for the development of disease-modifying therapies.